• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

结直肠癌患者肝转移灶中HER-2和HER-3的表达情况。

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

作者信息

Styczen Hanna, Nagelmeier Iris, Beissbarth Tim, Nietert Manuel, Homayounfar Kia, Sprenger Thilo, Boczek Ute, Stanek Kathrin, Kitz Julia, Wolff Hendrik A, Ghadimi B Michael, Middel Peter, Liersch Torsten, Rüschoff Josef, Conradi Lena-Christin

机构信息

Department of General, Visceral and Pediatric Surgery, University Medical Center, Göttingen, Germany.

Targos Molecular Pathology, Pathology Nordhessen, Kassel, Germany.

出版信息

Oncotarget. 2015 Jun 20;6(17):15065-76. doi: 10.18632/oncotarget.3527.

DOI:10.18632/oncotarget.3527
PMID:25915155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4558136/
Abstract

OBJECTIVE

In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value.

PATIENTS AND METHODS

Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months.

RESULTS

Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037).

CONCLUSIONS

HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

摘要

目的

在本研究中，我们评估了结直肠癌肝转移（CRLM）患者中HER-2和HER-3的表达频率。我们分析了HER-2和HER-3作为治疗靶点的潜力，并评估了它们的预后价值。

患者与方法

共纳入208例CRLM患者。在诊断性穿刺活检（n = 29）或切除标本（n = 179）的转移组织中测定HER-2和HER-3的表达。免疫组织化学（IHC）评分和原位杂交（ISH）扩增结果与临床参数相关，并与179例接受手术切除患者的癌症特异性生存（CSS）和总生存（OS）相关。平均随访时间为56.7个月。

结果

在8.2%的CRLM中发现HER-2状态阳性（IHC评分2+/ISH+和IHC 3+）。在75.0%的肝转移中检测到HER-3高表达（IHC评分2+和IHC 3+）。确定了肝切除术后的CSS，且其与HER-2状态无关（p = 0.963）；然而，HER-3对HER-3过表达的患者具有预后意义，其病程良好（p = 0.037）。

结论

HER-2过表达仅发生在8%的CRLM患者中，但在75%的病例中，HER-3在CRLM中频繁过表达。因此，HER-2尤其是HER-3可作为多模式治疗方法中的新靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/37f1945f5832/oncotarget-06-15065-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/276fdf3985ff/oncotarget-06-15065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/e015a3e7b028/oncotarget-06-15065-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/9b3c35ff4947/oncotarget-06-15065-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/37f1945f5832/oncotarget-06-15065-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/276fdf3985ff/oncotarget-06-15065-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/e015a3e7b028/oncotarget-06-15065-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/9b3c35ff4947/oncotarget-06-15065-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b7d/4558136/37f1945f5832/oncotarget-06-15065-g004.jpg

相似文献

1
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.结直肠癌患者肝转移灶中HER-2和HER-3的表达情况。
Oncotarget. 2015 Jun 20;6(17):15065-76. doi: 10.18632/oncotarget.3527.
2
AN APPROACH TO THE DETERMINATION OF A PROGNOSTIC INDEX FOR THE SCOPE OF SIMULTANEOUS RESECTION IN PATIENTS WITH SYNCHRONOUS COLORECTAL LIVER METASTASES.
Khirurgiia (Sofiia). 2014(4):21-8.
3
HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.原发性结直肠癌患者中HER3蛋白表达与HER2阳性的关系：临床相关性及预后价值
Virchows Arch. 2015 Jun;466(6):645-54. doi: 10.1007/s00428-015-1747-2. Epub 2015 Mar 5.
4
HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.HER-2/neu 过表达是肠型和早期胃癌患者的独立预后因素。
J Clin Gastroenterol. 2012 Apr;46(4):e31-7. doi: 10.1097/MCG.0b013e31823457ea.
5
Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.遗传证据表明，肿瘤内 T 细胞的增殖和激活与接受手术切除的结直肠癌肝转移患者的复发和生存相关。
Cancer Immunol Res. 2015 Apr;3(4):380-8. doi: 10.1158/2326-6066.CIR-14-0212. Epub 2015 Jan 19.
6
Weak stromal Caveolin-1 expression in colorectal liver metastases predicts poor prognosis after hepatectomy for liver-only colorectal metastases.结直肠癌肝转移瘤中基质层小窝蛋白-1 表达较弱预示着仅行肝切除术治疗肝转移性结直肠癌的预后不良。
Sci Rep. 2017 May 17;7(1):2058. doi: 10.1038/s41598-017-02251-9.
7
Differential CXC receptor expression in colorectal carcinomas.结直肠癌中CXC受体的差异表达
Scand J Immunol. 2008 Dec;68(6):635-44. doi: 10.1111/j.1365-3083.2008.02163.x. Epub 2008 Oct 6.
8
Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases.缺氧诱导因子-1α的过表达是结直肠肝转移灶根治性切除术后复发的独立危险因素。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S527-36. doi: 10.1245/s10434-013-2945-2. Epub 2013 Jun 9.
9
Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis.术前放疗治疗直肠癌中 HER-2 的表达：一种潜在的预测转移的生物标志物。
Dis Colon Rectum. 2014 May;57(5):602-7. doi: 10.1097/DCR.0000000000000107.
10
Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases.原发性结直肠癌与其相应转移灶之间HER2表达的比较。
Cancer Med. 2014 Jun;3(3):674-80. doi: 10.1002/cam4.228. Epub 2014 Mar 25.

引用本文的文献

1
Adoptive immune cell therapy for colorectal cancer.结直肠癌的过继性免疫细胞疗法。
Front Immunol. 2025 Apr 1;16:1557906. doi: 10.3389/fimmu.2025.1557906. eCollection 2025.
2
Emerging importance of HER3 in tumorigenesis and cancer therapy.HER3在肿瘤发生和癌症治疗中的重要性日益凸显。
Nat Rev Clin Oncol. 2025 May;22(5):348-370. doi: 10.1038/s41571-025-01008-y. Epub 2025 Mar 14.
3
Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.转移性结直肠癌中 HER2 状态的时空异质性。

本文引用的文献

1
Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma.德国结直肠癌肝转移的治疗：基于人群的对5772例原发性结直肠腺癌的十年分析
BMC Cancer. 2014 Nov 4;14:810. doi: 10.1186/1471-2407-14-810.
2
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.奥沙利铂、氟尿嘧啶和亚叶酸钙与氟尿嘧啶和亚叶酸钙作为术前放化疗后局部进展期直肠癌的辅助化疗（ADORE）：一项开放标签、多中心、2 期、随机对照临床试验。
Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.
3
Diagn Pathol. 2024 Jun 22;19(1):88. doi: 10.1186/s13000-024-01508-y.
4
Dissecting tumor microenvironment from spatially resolved transcriptomics data by heterogeneous graph learning.通过异质图学习从空间分辨转录组学数据中剖析肿瘤微环境
Nat Commun. 2024 Jun 13;15(1):5057. doi: 10.1038/s41467-024-49171-7.
5
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target.HER-3在晚期结直肠癌中的表面表达增加，这代表了一个潜在的治疗靶点。
Cell Death Discov. 2023 Oct 28;9(1):400. doi: 10.1038/s41420-023-01692-8.
6
Cell Therapy as Target Therapy against Colon Cancer Stem Cells.细胞治疗作为针对结肠癌干细胞的靶向治疗。
Int J Mol Sci. 2023 May 3;24(9):8163. doi: 10.3390/ijms24098163.
7
Advances in adoptive cellular therapy for colorectal cancer: a narrative review.结直肠癌过继性细胞治疗的进展：一项叙述性综述
Ann Transl Med. 2022 Dec;10(24):1404. doi: 10.21037/atm-22-6196.
8
HER3 Alterations in Cancer and Potential Clinical Implications.癌症中的HER3改变及其潜在临床意义。
Cancers (Basel). 2022 Dec 14;14(24):6174. doi: 10.3390/cancers14246174.
9
EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.结直肠癌原发肿瘤及其淋巴结转移配对组织中 EGFR、HER2 和 HER3 蛋白的表达。
Sci Rep. 2022 Jul 28;12(1):12894. doi: 10.1038/s41598-022-17210-2.
10
Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer.哪些患者容易发生肝转移？结直肠癌肝转移异时性发生的危险因素研究进展。
Eur J Med Res. 2022 Jul 25;27(1):130. doi: 10.1186/s40001-022-00759-z.
Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis.HER-2/neu对结直肠癌预后无影响：一项荟萃分析。
Asian Pac J Cancer Prev. 2014;15(14):5551-6. doi: 10.7314/apjcp.2014.15.14.5551.
4
The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies.HER-2/neu过表达在结直肠癌中的预后价值：来自16项研究的证据。
Tumour Biol. 2014 Nov;35(11):10799-804. doi: 10.1007/s13277-014-2376-0. Epub 2014 Jul 31.
5
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.来自ToGA研究的HER2筛查数据：针对胃及胃食管交界癌中的HER2靶点
Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20.
6
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).多学科综合治疗方案下初始不可切除结直肠癌肝转移患者接受 FOLFOX/西妥昔单抗或 FOLFIRI/西妥昔单抗治疗的生存情况（CELIM 研究）。
Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.
7
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.曲妥珠单抗或拉帕替尼联合标准化疗用于HER2阳性乳腺癌：GEICAM/2006-14试验结果
Br J Cancer. 2014 Mar 4;110(5):1139-47. doi: 10.1038/bjc.2013.831. Epub 2014 Jan 23.
8
New HER2-positive targeting agents in clinical practice.临床实践中的新型 HER2 阳性靶向药物。
Curr Oncol Rep. 2014;16(1):359. doi: 10.1007/s11912-013-0359-8.
9
HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome.原发性结直肠癌患者及其相应淋巴结转移中 HER3 的表达与临床结局的关系。
Eur J Cancer. 2014 Feb;50(3):656-62. doi: 10.1016/j.ejca.2013.11.008. Epub 2013 Nov 30.
10
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.EMILIA 研究的患者报告结局：曲妥珠单抗-美坦新偶联物（T-DM1）对比卡培他滨和拉帕替尼用于人表皮生长因子受体 2 阳性局部晚期或转移性乳腺癌的随机 3 期研究。
Cancer. 2014 Mar 1;120(5):642-51. doi: 10.1002/cncr.28465. Epub 2013 Nov 12.